Tenet Healthcare Corporation New financials
$257.60−0.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.31B | $20.68B | $20.56B | $19.37B | $19.68B | $17.64B | $18.48B | $18.31B | $19.18B | $19.62B |
| Gross profit | $21.31B | $20.68B | $20.56B | $19.37B | $19.68B | $17.64B | $18.48B | $18.31B | $19.18B | $19.62B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $3.25B | $2.78B | $2.26B | $2.12B | $2.21B | $924.0M | $1.38B | $1.36B | $825.0M | $965.0M |
| Net income | $1.41B | $3.20B | $611.0M | $411.0M | $914.0M | $399.0M | -$215.0M | $104.0M | -$704.0M | -$192.0M |
| Net margin | 6.6% | 15.5% | 3.0% | 2.1% | 4.6% | 2.3% | −1.2% | 0.6% | −3.7% | −1.0% |
| Diluted EPS | $15.49 | $32.70 | $5.71 | $3.79 | $8.42 | $3.75 | $-2.08 | $1.00 | $-7.00 | $-1.93 |
| EBITDA | $4.30B | $3.73B | $3.31B | $3.25B | $3.26B | $2.12B | $2.55B | $2.41B | $2.26B | $2.31B |
| Operating cash flow | $3.54B | $2.05B | $2.37B | $1.08B | $1.57B | $3.41B | $1.23B | $1.05B | $1.20B | $558.0M |
| Free cash flow | $2.53B | $1.12B | $1.62B | $321.0M | $910.0M | $2.87B | $563.0M | $432.0M | $493.0M | -$317.0M |
| Diluted shares | 90.8M | 97.9M | 104.8M | 110.5M | 108.6M | 106.3M | 103.4M | 103.9M | 100.6M | 99.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.88B | $3.02B | $1.23B | $858.0M | $2.36B | $2.45B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $13.25B | $13.32B | $15.20B | $15.29B | $15.85B | $15.97B |
| Total assets | $29.68B | $28.94B | $28.31B | $27.16B | $27.58B | $27.11B |
| Total liabilities | $20.70B | $20.39B | $22.80B | $22.55B | $23.32B | $24.22B |
| Shareholders' equity | $6.02B | $5.82B | $3.12B | $2.46B | $2.05B | $937.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology